Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis

Published:2014-12 Issue: Volume:262 Page:66-71
ISSN:0014-4886
Container-title:Experimental Neurology
language:en
Short-container-title:Experimental Neurology

Author:

Varrin-Doyer Michel,Zamvil Scott S.^ORCID,Schulze-Topphoff Ulf

Funder

National Institutes of Health

NMSS

Guthy Jackson Charitable Foundation

Dana Foundation

Maisin Foundation

Teva Pharmaceuticals, Inc.

National Multiple Sclerosis Society (NMSS)

Deutsche Forschungsgemeinschaft

Publisher

Elsevier BV

Subject

Developmental Neuroscience,Neurology

Reference39 articles.

1. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis;Aharoni;J. Neuroimmunol.,2012

2. Updates on the treatment of lupus nephritis;Bomback;J. Am. Soc. Nephrol.,2010

3. Insight into the mechanism of laquinimod action;Bruck;J. Neurol. Sci.,2011

4. Laquinimod, a once-daily oral drug in development for the treatment of relapsing–remitting multiple sclerosis;Bruck;Expert. Rev. Clin. Pharmacol.,2012

5. Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination;Bruck;Acta Neuropathol.,2012

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study;The Lancet Neurology;2024-03

2. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-01-04

3. Monocytes in multiple sclerosis;Mechanisms of Disease Pathogenesis in Multiple Sclerosis;2024

4. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies;Cytokine & Growth Factor Reviews;2023-06

5. Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics;Frontiers in Immunology;2022-12-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3